Epigenetically Silenced Long Noncoding-Srhc Promotes Proliferation of Hepatocellular Carcinoma

Hao Zheng,Sen Yang,Yuan Yang,Sheng-Xian Yuan,Fu-Quan Wu,Li-Li Wang,Hong-Li Yan,Shu-Han Sun,Wei-Ping Zhou
DOI: https://doi.org/10.1007/s00432-014-1871-4
2014-01-01
Journal of Cancer Research and Clinical Oncology
Abstract:Purpose To investigate the expression of SRHC and the role of SRHC in the pathogenesis of hepatocellular carcinoma (HCC). Methods We analyzed HCC samples and matched non-tumor liver tissues (controls) collected from 81 patients who underwent hepatectomy in Shanghai, China. The expression levels of SRHC were determined by quantitative reverse-transcription polymerase chain reaction. Statistical analyses were used to associate the levels of SRHC with tumor features and patient outcomes. Results We found that a lower SRHC expression level was significantly more frequent in tissues with a high serum a-fetoprotein level (positive, >20 µg/L, P = 0.004) and a low degree of differentiated tumors (poorly differentiated, P = 0.017). Furthermore, we found that the promoter region of SRHC contains a CpG-rich island and that SRHC is down-regulated in tumors by DNA methylation. Conclusion Here, we identified a new long noncoding RNA designated as SRHC that is capable of inhibiting cancer proliferation and is down-regulated in tumors at least partly by DNA methylation.
What problem does this paper attempt to address?